Amgen Turns To An Independent Review To Defend Rare Disease Drug In FDA Crosshairs

FDA concerns about Amgen's Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to withdraw Tavneos's approval, citing safety risks and alleged manipulation of clinical trial data. Amgen is defending the drug through an independent review analysis.